CStone Pharmaceuticals Co. Ltd. (CSPHF)
0.6892
0.00 (0.00%)
USD |
OTCM |
Nov 16, 16:00
CStone Pharmaceuticals Enterprise Value : 870.05M for Nov. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 16, 2026 | 870.05M |
| November 13, 2026 | 870.05M |
| November 12, 2026 | 870.05M |
| November 11, 2026 | 974.27M |
| November 10, 2026 | 974.27M |
| November 09, 2026 | 974.27M |
| November 06, 2026 | 974.27M |
| November 05, 2026 | 974.27M |
| November 04, 2026 | 974.27M |
| November 03, 2026 | 974.27M |
| November 02, 2026 | 974.27M |
| October 30, 2026 | 974.27M |
| October 29, 2026 | 974.27M |
| October 28, 2026 | 974.27M |
| October 27, 2026 | 974.27M |
| October 26, 2026 | 974.27M |
| October 23, 2026 | 974.27M |
| October 22, 2026 | 974.27M |
| October 21, 2026 | 974.27M |
| October 20, 2026 | 974.27M |
| October 19, 2026 | 974.27M |
| October 16, 2026 | 974.27M |
| October 15, 2026 | 974.27M |
| October 14, 2026 | 974.27M |
| October 13, 2026 | 974.27M |
| Date | Value |
|---|---|
| October 12, 2026 | 974.27M |
| October 09, 2026 | 974.27M |
| October 08, 2026 | 974.27M |
| October 07, 2026 | 974.27M |
| October 06, 2026 | 974.27M |
| October 05, 2026 | 974.27M |
| October 02, 2026 | 974.27M |
| October 01, 2026 | 974.27M |
| September 30, 2026 | 974.27M |
| September 29, 2026 | 854.23M |
| September 28, 2026 | 816.84M |
| September 25, 2026 | 918.83M |
| September 24, 2026 | 918.83M |
| September 23, 2026 | 918.83M |
| September 22, 2026 | 918.83M |
| September 21, 2026 | 918.83M |
| September 18, 2026 | 1.223B |
| September 17, 2026 | 1.223B |
| September 16, 2026 | 1.223B |
| September 15, 2026 | 1.223B |
| September 14, 2026 | 1.223B |
| September 11, 2026 | 1.223B |
| September 10, 2026 | 1.223B |
| September 09, 2026 | 1.223B |
| September 08, 2026 | 1.223B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ascletis Pharma, Inc. | 567.37M |
| RemeGen Co., Ltd. | 4.804B |
| InnoCare Pharma Ltd. | 2.178B |
| Adagene, Inc. | 194.71M |
| JW (Cayman) Therapeutics Co. Ltd. | -- |
Enterprise Value Related Metrics
| Earnings Yield | -5.82% |
| Normalized Earnings Yield | -5.688 |